Expert disagreements, alternative perspectives, and minority opinions.
Harm reduction proponents argue that large-scale trials like TRAVERSE provide the evidence needed to manage risks honestly rather than relying on historical fears. Regulators counter that FDA labelling for Aveed and Jatenzo explicitly excludes age-related hypogonadism, arguing that information on use for natural decline may enable unnecessary medicalisation or abuse.
“The TRAVERSE trial (5,246 men) confirmed that ART was non-inferior to placebo for the risk of major adverse cardiovascular events, providing reassurance on MACE.”
Editorial Context
Before TRAVERSE, significant clinical fear existed that any testosterone use drastically increased heart attack risk. The researchers provided high-rigour data to allow for safer clinical application.
Proponents of the 'mild' label point to the absence of hepatotoxicity and the more stable hormonal environment provided by TU's long half-life (injectable) or lymphatic absorption (oral). Critics argue the label is misleading: TU consistently elevates hematocrit and blood pressure, carries a rare but serious POME risk for injectables, and the TRAVERSE trial identified atrial fibrillation and AKI signals. The liver is protected, but the cardiovascular and renal systems bear measurable load.
“Oral TU formulations bypass first-pass hepatic metabolism via the lymphatic system, avoiding the liver toxicity of 17-alpha-alkylated steroids.”
Editorial Context
TU is often framed as 'mild' because it does not cause severe liver injury. This framing obscures its cardiovascular and haematological burden.
For diagnosed hypogonadism, TU is thoroughly studied with predictable dose-response outcomes. For performance-enhancement use (doses 2 to 10 times therapeutic), the safety profile is a data-free zone. Experts warn that the documented safety of therapeutic TU is incorrectly used to justify unstudied higher doses.
“TU effectively restores serum testosterone levels to the eugonadal range in hypogonadal men with high confidence from direct clinical evidence.”
Editorial Context
Extensive Phase III trials have mapped how TU affects bone density and lean mass in men with clinically diagnosed deficiencies. These data do not extend to supraphysiological dosing.
Strong consensus holds that neurodevelopmental and skeletal risks make TU inappropriate for males under 25. For men over 45, TU provides meaningful muscle and bone preservation, but TRAVERSE identified higher AF (3.5% vs 2.4%) and AKI rates in this older cohort. The debate centres on whether quality-of-life gains outweigh statistically significant increases in non-fatal cardiac events.
“Administration of exogenous testosterone in males under 25 carries a high-confidence risk of premature epiphyseal closure (growth plate fusion).”
Editorial Context
While TU builds bone density in older men (a benefit), the same mechanism in younger men permanently terminates linear growth and potentially disrupts brain structure maturation.
TU advocates argue it remains the only reliable method for full physiological testosterone restoration. Peptide proponents counter that for specific goals like visceral fat reduction, Tesamorelin achieves 15 to 20% VAT reduction without HPG axis suppression. The framing depends on the clinical goal: full androgenic restoration versus targeted metabolic modulation without systemic endocrine shutdown.
“Steroids offer a magnitude of effect (especially for absolute strength and mass) that peptides, which rely on the body's varying ability to respond to upstream signals, cannot consistently match.”
Editorial Context
As 'peptide replacement' becomes a trend, experts highlight that TU provides a direct, predictable androgenic drive that indirect peptides cannot replicate.